Literature DB >> 10931025

Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma.

T M Hughes1, R P A'Hern, J M Thomas.   

Abstract

BACKGROUND: The appropriate management of melanoma metastatic to inguinal lymph nodes remains controversial. The aim of this study was to identify disease- and treatment-related factors that influence the outcome of patients undergoing therapeutic groin dissection for clinically detectable melanoma lymph node metastases.
METHODS: A retrospective analysis was performed on data collected from the case records of patients who had a therapeutic inguinal lymph node dissection performed between 1984 and 1998.
RESULTS: Some 132 patients were suitable for inclusion. Sixty patients had superficial inguinal lymph node dissection (SLND) and 72 had combined superficial inguinal and pelvic lymph node dissection (CLND). There was no difference in postoperative morbidity or major lymphoedema between SLND and CLND. The overall survival rate was 34 per cent at 5 years. On univariate analysis, age (P = 0.003), the number of involved superficial lymph nodes (P = 0.001) and the presence of extracapsular spread (P = 0.003) were found to have a significant impact on survival. The presence or absence of pelvic lymph node metastases in patients who had CLND was a significant prognostic factor for survival (5-year survival 19 versus 47 per cent; P = 0.015).
CONCLUSION: The prognosis of patients with clinically detectable melanoma metastases to the groin is variable and related to the biological characteristics of each case. CLND provided additional prognostic information and optimal regional control with no increased morbidity compared with SLND.

Entities:  

Mesh:

Year:  2000        PMID: 10931025     DOI: 10.1046/j.1365-2168.2000.01439.x

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  20 in total

1.  Enhanced postoperative lymphatic staging of malignant melanoma by endoscopically assisted iliacoinguinal dissection.

Authors:  I M Ising; A Bembenek; R Gutzmer; F Köckerling; K T Moesta
Journal:  Langenbecks Arch Surg       Date:  2011-12-24       Impact factor: 3.445

2.  Risk evaluation in cutaneous melanoma patients undergoing lymph node dissection: impact of POSSUM.

Authors:  F Egberts; C Hartje; C Schafmayer; K C Kaehler; W von Schönfels; A Hauschild; T Becker; J H Egberts
Journal:  Ann R Coll Surg Engl       Date:  2011-10       Impact factor: 1.891

3.  Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients.

Authors:  Sharon B Chang; Robert L Askew; Yan Xing; Storm Weaver; Jeffrey E Gershenwald; Jeffrey E Lee; Richard Royal; Anthony Lucci; Merrick I Ross; Janice N Cormier
Journal:  Ann Surg Oncol       Date:  2010-03-25       Impact factor: 5.344

Review 4.  Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites.

Authors:  Amod A Sarnaik; Jonathan S Zager; Vernon K Sondak
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

5.  Regional control and morbidity after superficial groin dissection in melanoma.

Authors:  Amber L Shada; Craig L Slingluff
Journal:  Ann Surg Oncol       Date:  2010-12-07       Impact factor: 5.344

6.  Wound complications after inguinal lymph node dissection for melanoma: is ACS NSQIP adequate?

Authors:  Carly E Glarner; David Y Greenblatt; Robert J Rettammel; Heather B Neuman; Sharon M Weber
Journal:  Ann Surg Oncol       Date:  2013-01-22       Impact factor: 5.344

7.  Role of radiotherapy in melanoma management.

Authors:  Primoz Strojan
Journal:  Radiol Oncol       Date:  2010-03-18       Impact factor: 2.991

8.  Inguinal or inguino-iliac/obturator lymph node dissection after positive inguinal sentinel lymph node in patients with cutaneous melanoma.

Authors:  Nebojsa Glumac; Marko Hocevar; Vesna Zadnik; Marko Snoj
Journal:  Radiol Oncol       Date:  2012-07-24       Impact factor: 2.991

9.  Therapeutic lymph node dissection in melanoma: different prognosis for different macrometastasis sites?

Authors:  K P Wevers; E Bastiaannet; H P A M Poos; R J van Ginkel; J T Plukker; H J Hoekstra
Journal:  Ann Surg Oncol       Date:  2012-05-17       Impact factor: 5.344

10.  Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors.

Authors:  Nicola Mozzillo; Corrado Caracò; Ugo Marone; Gianluca Di Monta; Anna Crispo; Gerardo Botti; Maurizio Montella; Paolo Antonio Ascierto
Journal:  World J Surg Oncol       Date:  2013-02-04       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.